Results of Annual General Meeting

May 31, 2023

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 2092B
Advanced Medical Solutions Grp PLC
31 May 2023
 

31 May 2023

 

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Results of Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that at the Company’s Annual General Meeting held today at 11 am at the Offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 28 April 2023.

 

The poll results were as follows.

Resolution

Title

 For

For %

Against

Against %

Total Votes

% Issued Capital

1

FINANCIAL STATEMENTS

      135,930,178

100.00%

              2,600

0.00%

      135,932,778

62.61%

2

REMUNERATION REPORT

      134,448,331

98.78%

        1,660,110

1.22%

      136,108,441

62.69%

3

AUDITOR REMUNERATION

      129,945,308

95.88%

        5,579,727

4.12%

      135,525,035

62.42%

4

RE-ELECT P ALLEN

      121,131,315

88.99%

      14,989,308

11.01%

      136,120,623

62.70%

5

RE-ELECT G COOK

      123,309,347

90.59%

      12,804,964

9.41%

      136,114,311

62.69%

6

RE-ELECT D LE FORT

      123,977,756

91.08%

      12,136,555

8.92%

      136,114,311

62.69%

7

ELECT L SHANAHAN

      136,068,717

99.97%

             45,594

0.03%

      136,114,311

62.69%

8

RE-ELECT C MEREDITH

      131,687,725

96.74%

        4,434,124

3.26%

      136,121,849

62.70%

9

RE-ELECT E JOHNSON

      133,113,126

97.80%

        3,001,185

2.20%

      136,114,311

62.69%

10

FINAL DIVIDEND

      136,127,581

100.00%

                 278

0.00%

      136,127,859

62.70%

11

ALLOT SHARES*

      135,448,934

99.52%

           654,222

0.48%

      136,103,156

62.69%

12

PRE-EMPTION RIGHTS*

      129,949,465

95.47%

        6,165,524

4.53%

      136,114,989

62.69%

13

PURCHASE SHARES*

      135,042,435

99.95%

             63,012

0.05%

      135,105,447

62.23%

 

*  Special Resolution

Notes:

1.  Votes “For” and “Against” are expressed as a percentage of votes received.

2.  A “Vote withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.

3.  Total number of shares in issue at close of business on 26 May = 217,109,419 shares. 62.63% of the voting capital was instructed.

 

– Ends –

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations



 

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson




HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish


 

About Advanced Medical Solutions Group plc see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Austria, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

RAGFLFIVEVILVIV

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.